[prev in list] [next in list] [prev in thread] [next in thread]
List: snap-users
Subject: (KAME-snap 7316) This is Getting Along877
From: "Paulette" <treeoflife () nwcom ! co ! kr>
Date: 2002-12-20 20:46:49
[Download RAW message or body]
<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List
href="./12-18-02%20RJVM%20edited%20version%202%20jrs-stacy%20optin_files/filelist.xml">
<link rel=Edit-Time-Data
href="./12-18-02%20RJVM%20edited%20version%202%20jrs-stacy%20optin_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>This message has been sent to you in compliance with our strict anti </title>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Author>Melanie Marco</o:Author>
<o:Template>Normal</o:Template>
<o:LastAuthor>Paul W</o:LastAuthor>
<o:Revision>2</o:Revision>
<o:TotalTime>55</o:TotalTime>
<o:Created>2002-12-19T18:35:00Z</o:Created>
<o:LastSaved>2002-12-19T18:35:00Z</o:LastSaved>
<o:Pages>4</o:Pages>
<o:Words>1427</o:Words>
<o:Characters>8136</o:Characters>
<o:Lines>67</o:Lines>
<o:Paragraphs>16</o:Paragraphs>
<o:CharactersWithSpaces>9991</o:CharactersWithSpaces>
<o:Version>9.2720</o:Version>
</o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
<w:SpellingState>Clean</w:SpellingState>
<w:GrammarState>Clean</w:GrammarState>
</w:WordDocument>
</xml><![endif]-->
<style>
<!--
span.SPELLE
{mso-spl-e:yes;}
span.GRAME
{mso-gram-e:yes;}
/* Font Definitions */
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:553679495 -2147483648 8 0 66047 0;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:536871559 0 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-parent:"";
margin:0in;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{color:blue;
text-decoration:underline;
text-underline:single;}
p
{margin-right:0in;
mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;
margin-left:0in;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.25in 1.0in 1.25in;
mso-header-margin:.5in;
mso-footer-margin:.5in;
mso-paper-source:0;}
div.Section1
{page:Section1;}
/* List Definitions */
@list l0
{mso-list-id:18090482;
mso-list-template-ids:1595051474;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
-->
</style>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags" \
name="State"/><o:SmartTagType \
namespaceuri="urn:schemas-microsoft-com:office:smarttags" \
name="City"/><o:SmartTagType \
namespaceuri="urn:schemas-microsoft-com:office:smarttags" \
name="country-region"/><o:SmartTagType \
namespaceuri="urn:schemas-microsoft-com:office:smarttags" \
name="place"/><o:SmartTagType \
namespaceuri="urn:schemas-microsoft-com:office:smarttags" \
name="PlaceName"/><o:SmartTagType \
namespaceuri="urn:schemas-microsoft-com:office:smarttags" name="PlaceType"/> <meta \
http-equiv=Content-Language content=en-us> </head>
<body lang=EN-US link=blue vlink=blue style='tab-interval:.5in'>
<div class=Section1>
<div id=messageBody>
<p class=MsoNormal align=center style='text-align:center'> <o:p></o:p></p>
<div align=center>
<table border=1 cellspacing=0 cellpadding=0 width="63%" style='width:63.1%;
mso-cellspacing:0in;margin-left:-.4pt;border:outset #89BE65 1.5pt;mso-padding-alt:
5.25pt 5.25pt 5.25pt 5.25pt' height=71 bordercolordark="#000000"
bordercolorlight="#000000">
<tr style='height:329.25pt;mso-yfti-irow:0'>
<td width="100%" valign=top style='width:100.0%;border:inset #89BE65 .75pt;
padding:5.25pt 5.25pt 5.25pt 5.25pt;height:329.25pt'>
<div align=center>
<table border=1 cellpadding=0 width="75%" style='width:75.0%;mso-cellspacing:
1.5pt;margin-left:.5in;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-yfti-irow:0'>
<tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
<td style='background:#003300;padding:.75pt .75pt .75pt .75pt'>
<p class=MsoNormal align=center style='text-align:center'><b><i><span
style='font-size:24.0pt;color:white'>STOCK ALERT</span></i></b></p>
</td>
</tr>
</table>
</div>
<p align=center style='margin-right:.5in;margin-left:.5in;text-align:center'><b><span
style='font-size:10.0pt;font-family:Verdana'> </span></b><b><i><u><span
style='font-family:Verdana;color:#0000A0'><a
href="http://biz.yahoo.com/n/r/rjvn.ob.html">RJV Networks, Inc. (OTC BB:
RJNV)</a></span></u></i></b></p>
<p style='margin-top:0in;margin-right:.5in;margin-bottom:0in;margin-left:
.5in;margin-bottom:.0001pt'><b><i><span style='font-family:Verdana'>TARGET
Price $4 -to- $6 in January 2003<span style='color:#0000A0'><br>
</span></span></i></b></p>
<p style='margin-top:0in;margin-right:.5in;margin-bottom:0in;margin-left:
.5in;margin-bottom:.0001pt'><b><span \
style='font-family:Verdana;color:#0000A0'>Tonight:</span></b><b><span \
style='font-family:Verdana;color:#3A8357'> </span></b><b><span \
style='font-family:Verdana;color:#0000A0'> </span></b><b><span \
style='font-size:10.0pt;font-family:Verdana;color:#5F5F5F'>RJNV holds exclusive \
licenses to state-of-the-art bio-technology developed at \
<st1:place><st1:PlaceType>University</st1:PlaceType> of \
<st1:PlaceName>Michigan</st1:PlaceName></st1:place> and the Cancer Control Agency of \
B.C. that experts are using to develop therapies believed to be capable of treating \
most cancers. </span></b></p> <p \
style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt; \
font-family:Verdana;color:#5F5F5F'>Through an acquisition of BioKinetix Research, \
Inc. (currently underway), RJVN is rapidly completing the development of a therapy \
for cancer that will make a lasting impression on the multibillion dollar bio-tech \
industry. Read more about this exciting up and comer below.</span></b> </p>
<div class=MsoNormal align=center style='margin-top:0in;margin-right:.5in;
margin-bottom:0in;margin-left:.5in;margin-bottom:.0001pt;text-align:center'>
<hr size=2 width="100%" align=center>
</div>
<div align=center>
<table border=1 cellspacing=0 cellpadding=0 width="69%" style='width:69.0%;
mso-cellspacing:0in;margin-left:.5in;border:outset black .75pt;mso-padding-alt:
3.75pt 3.75pt 3.75pt 3.75pt' height=86 bordercolordark="#000000"
bordercolorlight="#000000">
<tr style='height:58.5pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'>
<td width="100%" style='width:100.0%;border:inset black .75pt;background:
#F0F0F0;padding:3.75pt 3.75pt 3.75pt 3.75pt;height:58.5pt'>
<p class=MsoNormal><b><span style='font-size:10.0pt;font-family:Verdana;
color:#3A8357'>Company Name </span></b><b><span style='font-size:10.0pt;
font-family:Verdana'> <span
style='color:#5F5F5F'> </span><span style='color:#022051'>RJV Networks,
Inc.</span><br>
<span style='color:#3A8357'>Symbol </span> <span
style='color:#3A8357'>
</span><span \
style='color:#5F5F5F'> </span><span \
style='color:#022051'>RJVN</span><span style='color:#3A8357'><br> Current \
Price </span><span
style='color:#5F5F5F'> </span><span style='color:#022051'> \
$0.26</span><span style='color:#3A8357'><br>
52 Week High</span><span style='color:#5F5F5F'> </span><span
style='color:black'> </span><span \
style='color:#3A8357'> </span><span \
style='color:#022051'>$2.10</span><span style='color:#3A8357'><br> 52 Week
Low
</span><span style='color:#022051'>$0.26</span></span></b></p>
<p><b><span style='font-family:Verdana;color:#022051'>Target $4 -to-
$6 Q1/2003</span></b></p>
</td>
</tr>
</table>
</div>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-family:
Verdana;color:#0000A0'>Investment Highlights</span></b></p>
<p class=MsoNormal style='margin-right:.5in;mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list:
l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span
style='font:7.0pt "Times New \
Roman"'> \
</span></span><![endif]><span style='font-size:10.0pt;font-family:Verdana; \
color:#0000A0'>RJVN </span><span \
style='font-size:10.0pt;font-family:Verdana'>projects<b> it will be able to treat \
most cancers with its combined targeted therapy treatment which is based upon an \
astounding discovery by a molecular biologist at the \
<st1:place><st1:PlaceType>Univ.</st1:PlaceType> of \
<st1:PlaceName>Michigan</st1:PlaceName></st1:place>
- The causal link to breast and most other malignancies and cancers in the
protein Mammastatin.</b></span></p>
<p class=MsoNormal style='margin-right:.5in;mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list:
l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span
style='font:7.0pt "Times New \
Roman"'> \
</span></span><![endif]> </p> <p class=MsoNormal \
style='margin-right:.5in;mso-margin-top-alt:auto; \
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list: l0 level1 \
lfo3;tab-stops:list .5in'><![if !supportLists]><span \
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span \
style='font:7.0pt "Times New Roman"'> \
</span></span><![endif]><span style='font-size:10.0pt;font-family:Verdana'>RJVN has \
developed a series of cancer treatment therapies which utilize pan-cancer market \
antibodies. Antibody therapies do not create chemical toxicity and, as such, are \
fast tracked through the regulatory approval process. Using this approach, RJVN \
is targeted to enter testing for its products in six months.</span></p>
<p class=MsoNormal style='margin-right:.5in;mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list:
l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span
style='font:7.0pt "Times New \
Roman"'> \
</span></span><![endif]> </p> <p class=MsoNormal \
style='margin-right:.5in;mso-margin-top-alt:auto; \
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list: l0 level1 \
lfo3;tab-stops:list .5in'><![if !supportLists]><span \
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span \
style='font:7.0pt "Times New Roman"'> \
</span></span><![endif]><b><span style='font-size:10.0pt;font-family:Verdana; \
color:#306D48'>RJVN's</span></b><span style='font-size:10.0pt;font-family: Verdana'> \
combination of two leading, well known technologies previously announced by BioCurex \
and InNexus Corp along with RJVN's key MAb protein replicating technology has \
allowed the Company to create a series of patented therapeutic products that many \
molecular biologists believe will <b><i>treat most cancers.</i></b></span></p>
<p class=MsoNormal style='margin-right:.5in;mso-margin-top-alt:auto;
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list:
l0 level1 lfo3;tab-stops:list .5in'><![if !supportLists]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span
style='font:7.0pt "Times New \
Roman"'> \
</span></span><![endif]> </p> <p class=MsoNormal \
style='margin-right:.5in;mso-margin-top-alt:auto; \
mso-margin-bottom-alt:auto;margin-left:1.0in;text-indent:-.25in;mso-list: l0 level1 \
lfo3;tab-stops:list .5in'><![if !supportLists]><span \
style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>ÿFFFFB7<span \
style='font:7.0pt "Times New Roman"'> \
</span></span><![endif]><b><span style='font-size:10.0pt;font-family:Verdana; \
color:#306D48'>RJVN</span></b><span style='font-size:10.0pt;font-family:Verdana; \
color:#306D48'>'s R&D and Management are led by Dr. John Todd, Dr. Charles \
Morgan (a world renowned molecular biologist and 5 other industry leading Dr's all \
with several years experience in bio-tech development. </span><o:p></o:p></p>
<div align=center>
<table border=1 cellspacing=0 cellpadding=0 width="92%" bgcolor=red
style='width:92.0%;mso-cellspacing:0in;background:red;border:outset white 1.5pt;
mso-padding-alt:5.25pt 5.25pt 5.25pt 5.25pt' bordercolordark="#ffffff"
bordercolorlight="#ffffff">
<tr style='mso-yfti-irow:0;mso-yfti-lastrow:yes'>
<td width="100%" style='width:100.0%;border:inset white .75pt;background:
#0000A0;padding:5.25pt 5.25pt 5.25pt 5.25pt'>
<p align=center style='text-align:center'><b><span style='font-size:13.5pt;
font-family:Verdana;color:#EEEEEE'>About the Company</span></b></p>
</td>
</tr>
</table>
</div>
<p style='margin-right:.5in;margin-left:.5in'><span style='font-size:10.0pt;
font-family:Verdana'>RJVN (through BioKinetix Research, Inc.) was formed
after Dr. John Todd, a very well known and respected oncological surgeon from
BC, approached us with the story of an astounding discovery that had been
made by molecular biologists at the University of Michigan. This
discovery was believed to be the causal link to breast cancer, the link is a
medium sized (53KD) protein called Mammastatin. The evidence is that
Mammastatin is the agent that, when present, prevents the development and
growth of malignant breast tumors. Mammastatin is freely expressed by the
epithelial cells in the breast and as such acts as a natural contra-agent to
malignant development. Women who develop breast cancer have NO or
extremely low levels of Mammastatin in their system. After testing
hundreds of women, no woman with normal Mammastatin levels has developed
breast cancer.</span></p>
<p style='margin-right:.5in;margin-left:.5in'><span style='font-size:10.0pt;
font-family:Verdana'>Dr. John Todd in conjunction with the Cancer Control
Agency of B.C. conducted compassionate trials on several terminally ill
patients (authorized by Health \
<st1:country-region><st1:place>Canada</st1:place></st1:country-region>) with a \
Mammastatin replacement program the results of which thoroughly convinced Dr. Todd \
of the direct link. The challenge existed from the fact that proteins are \
extremely difficult to sequence (replicate). Mammastatin has over 400 \
amino-acids in its chain, and, even if successful in sequencing, the synthetic \
replication is even more difficult. Finally the delivery of a protein, natural \
or synthetic, will now have to face the natural breakdown of the chain as it \
circulates through the body.</span></p> <p \
style='margin-right:.5in;margin-left:.5in'><span style='font-size:10.0pt; \
font-family:Verdana'>Dr. Charles Morgan is a world-renowned molecular biologist who \
has proposed an alternative approach to this problem. He is convinced, and \
several well known molecular biologists agree with him, that he can mimic the active \
component of the Mammastatin protein through the production of an anti-idiotypic \
monoclonal antibody (MAb). These MAbs are stable, target specific and will in \
all measure act like the native Mammastatin. To dramatically enhance the \
bio-activity of these anti-idiotypic monoclonal antibodies, RJNV will create \
Superantibodies through the use of InNexus' Super Antibody platform technology (see \
news for <a href="http://biz.yahoo.com/n/b/bocx.ob.html">OTC BB: BOCX</a> about this
technology). This technology allows the cross linking of antibodies to boost
their potency and resiliency.</span></p>
<p style='margin-right:.5in;margin-left:.5in'><span style='font-size:10.0pt;
font-family:Verdana'>As a result of the scientific approach implemented by
RJNV's BioKinetix (acquisition underway), the company has negotiated a
license from BioCurex <a href="http://biz.yahoo.com/n/b/bocx.ob.html">OTC BB:
BOCX</a> to develop therapeutic products based on their pan-cancer marker
antibodies. The combination of these two technologies gives RJVN the
potential to create a series of therapeutic products that will treat most
cancers.<o:p></o:p></span></p>
<p style='margin-right:.5in;margin-left:.5in'><span style='font-size:10.0pt;
font-family:Verdana'>Antibody therapies do not create chemical toxicity and,
as such, are fast tracked through the regulatory approval process. Using
this approach, RJVN is targeted to enter testing for its products in six
months.</span><o:p></o:p></p>
<table border=1 cellspacing=1 cellpadding=0 width="90%" style='width:90.0%;
mso-cellspacing:.7pt;margin-left:.5in;border:none;mso-padding-alt:0in 54pt 0in \
5.4pt' height=48>
<tr style='height:.5in;mso-yfti-irow:0;mso-yfti-lastrow:yes'>
<td width="100%" style='width:100.0%;border:none;background:#0000A0;
padding:.75pt .75pt .75pt .75pt;height:.5in'>
<p align=center style='text-align:center'><b><span style='font-size:13.5pt;
font-family:Verdana;color:#EEEEEE'>Industry Potential</span></b></p>
</td>
</tr>
</table>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt;
font-family:Verdana'>The potential market for RJVN's cancer treatment
therapies far outstrips any reasonable estimate to be made at this
time. As the Company implements its technology upon entering the market
test phase, we expect a large bio-tech or pharmaceutical mfr. to acquire the
Company for several hundred million.<o:p></o:p></span></b></p>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt;
font-family:Verdana'>Due to the Companies ability to fast track, beginning
clinical trials of its revolutionary cancer treatment in early 2003E,
exposure of its initial success will spread quickly. \
</span></b><o:p></o:p></p> <div align=center>
<table border=1 cellspacing=0 cellpadding=0 width="88%" bgcolor="#022051"
style='width:88.0%;mso-cellspacing:0in;margin-left:.5in;background:#022051;
border:none;mso-padding-alt:0in 5.4pt 0in 5.4pt' height=44>
<tr style='height:31.5pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'>
<td width="100%" style='width:100.0%;border:none;background:#0000A0;
padding:.75pt .75pt .75pt .75pt;height:31.5pt'>
<p align=center style='text-align:center'><b><span style='font-size:13.5pt;
font-family:Verdana;color:white'>Conclusion</span></b></p>
</td>
</tr>
</table>
</div>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt;
font-family:Verdana'>The Company will be participating in a road-show in
January and February of 2003, meeting with several institutional brokerage
houses in <st1:place><st1:City>San Francisco</st1:City>, <st1:State>New \
York</st1:State></st1:place>, and other major metro areas to showcase their \
technology. We expect many pension fund managers to begin positioning the \
stock in their portfolios sometime in Q1/2003 and Q2/2003.</span></b></p>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt;
font-family:Verdana'>The stock is highly undervalued currently due to the
fact that there has been no P/R done on the Company. Mass direct mail,
investment club profiles and other P/R related activities are beginning with
the issuance of this newsletter. We expect the stock to appreciate
significantly over the next 20-trading days.</span></b></p>
<p style='margin-right:.5in;margin-left:.5in'><b><span style='font-size:10.0pt;
font-family:Verdana'>TARGET Price $4 -to- $6 in January 2003</span></b></p>
<p style='margin-right:.5in;margin-left:.5in'> </p>
</td>
</tr>
<tr style='height:105.15pt;mso-yfti-irow:1'>
<td width="100%" valign=top style='width:100.0%;border:inset #89BE65 .75pt;
padding:5.25pt 5.25pt 5.25pt 5.25pt;height:105.15pt'>
<p class=MsoNormal><span \
style='font-size:7.5pt;font-family:Verdana'>******************* </span><b \
style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt; \
font-family:Verdana'>Special Offer</span></b><span style='font-size:7.5pt; \
font-family:Verdana'> *******************<o:p></o:p></span></p> <p \
class=MsoNormal><span style='font-size:10.0pt;font-family:Verdana'>If you would like \
to be included in our mailing list, you will<o:p></o:p></span></p> <p \
class=MsoNormal><span style='font-size:10.0pt;font-family:Verdana'>receive a 10 day \
free trial to a web site with real-time<o:p></o:p></span></p> <p \
class=MsoNormal><span style='font-size:10.0pt;font-family:Verdana'>Level II quotes, \
research reports from major providers, analyst upgrades/downgrade info, Bulletin \
Board Promotion/Syndication Calendar (1st of its kind), and access to our trading \
chat rooms<o:p></o:p></span></p> <p class=MsoNormal><span \
style='font-size:10.0pt;font-family:Verdana'>and to several message boards with real \
live professionals. Just<o:p></o:p></span></p> <p class=MsoNormal><span \
style='font-size:10.0pt;font-family:Verdana'>click on this link: <a \
href="mailto:stacylu@excite.com?subject=Opt-in">Opt-in</a> to send us an email, and \
you will be immediately added. <o:p></o:p></span></p> <p class=MsoNormal><span \
style='font-size:7.5pt;font-family:Verdana'> <o:p></o:p></span></p> </td>
</tr>
<tr style='height:210.0pt;mso-yfti-irow:2;mso-yfti-lastrow:yes'>
<td width="100%" valign=top style='width:100.0%;border:inset #89BE65 .75pt;
padding:5.25pt 5.25pt 5.25pt 5.25pt;height:210.0pt'>
<p class=MsoNormal><b style='mso-bidi-font-weight:normal'> </b><b
style='mso-bidi-font-weight:normal'><span style='font-size:7.5pt;font-family:
Verdana'>Disclaimer</span></b><span \
style='font-size:7.5pt;font-family:Verdana'> <br> Information within this email \
contains "forward looking statements" within the meaning of Section 27A of \
the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. \
Any statements that express or involve discussions with respect to predictions, \
expectations, beliefs, plans, projections, objectives, goals, assumptions or future \
events or performance are not statements of historical fact and may be "forward
looking statements."<br>
<br>
Forward looking statements are based on expectations, estimates and
projections at the time the statements are made that involve a number
of risks and uncertainties which could cause actual results or events to
differ materially from those presently anticipated. Forward looking statements
in this action may be identified through the use of words such as
"projects", "foresee", "expects",
"will," "anticipates," "estimates,"
"believes," "understands" or that by statements
indicating certain actions "may," "could," or
"might" occur. All information provided within this email
pertaining to investing, stocks, securities must be understood as information
provided and not investment advice. Emerging Equity Alert advises all readers
and subscribers to seek advice from a registered professional securities
representative before deciding to trade in stocks featured within this
email. None of the material within this report shall be construed as
any kind of investment advice.<br>
<br>
In compliance with the Securities Act of 1933, Section17(b), Emerging Stock
Alert discloses the receipt of 125,000 unrestricted shares of RJVN from a
third party for the publication of this report. Be aware of an inherent
conflict of interest resulting from such compensation due to our intent to
profit from the liquidation of these shares. Shares may be sold at any
time, even after positive statements have been made regarding the above
company. All factual information in this report was gathered from
public sources, including but not limited to SEC filings, Company Press Releases,
and Market Guide. Emerging Equity Alert believes this information
to be reliable but can make no guarantee as to its accuracy or completeness.
Use of the material within this email constitutes your acceptance of these
terms.</span></p>
</td>
</tr>
</table>
</div>
<p class=MsoNormal align=center style='text-align:center'><span
style='display:none;mso-hide:all'> <o:p></o:p></span></p>
<p class=MsoNormal> <o:p></o:p></p>
</div>
<table border=1 cellspacing=0 cellpadding=0 width=333 style='width:249.75pt;
margin-left:152.55pt;border-collapse:collapse;border:none;mso-border-alt:solid \
windowtext .5pt; mso-padding-alt:0in 5.4pt 0in \
5.4pt;mso-yfti-tbllook:191;mso-border-insideh:.5pt solid windowtext; \
mso-border-insidev:.5pt solid windowtext'> <tr \
style='height:56.95pt;mso-yfti-irow:0;mso-yfti-lastrow:yes'> <td valign=top \
style='border:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt; height:56.95pt'>
<p class=MsoNormal>
<meta http-equiv=pragma content=no-cache>
<b style='mso-bidi-font-weight:normal'><span style='font-size:10.0pt;
font-family:Verdana'>
<meta http-equiv=cache-control content=no-cache>
<meta http-equiv=expires content="Sun, 21 Mar 1999 06:05:29 GMT">
****** Advertising Disclaimer ******<o:p></o:p></span></b></p>
<p class=MsoNormal><span style='font-size:10.0pt;font-family:Verdana'>We have
received monetary payment for this mailing service We hold no stocks and hold
no personal interest in this company.</span></p>
</td>
</tr>
</table>
<p class=MsoNormal align=center style='text-align:center'> </p>
<p class=MsoNormal align=center style='text-align:center'> </p>
<p class=MsoNormal> </p>
<p class=MsoNormal><span style='font-size:7.5pt;font-family:Arial;color:black'>This
message has been sent to you in compliance with our strict anti-abuse
regulations. We will continue to bring you valuable offers on the products and
services that interest you most. If you do not wish to receive further
mailings, please click below. You may then rest-assured that you will
never receive another email from us again. </span><b><span
style='font-size:7.5pt;font-family:Tahoma;color:black'>We respect all removal
requests.</span></b><span style='font-size:7.5pt;font-family:Arial;color:black'>
To be immediately removed from our mailing lists just click on this link <a
href="mailto:krq42@yahoo.com?subject=Unsubscribe%20me%20please">UNSUBSCRIBE ME
PLEASE</a> . This message is an advertisement. Copyright 2000, 2001, 2002 all
rights reserved. </span></p>
</div>
</body>
</html>
[prev in list] [next in list] [prev in thread] [next in thread]
Configure |
About |
News |
Add a list |
Sponsored by KoreLogic